Earnings
CG Oncology Cretostimogene Nears Key PIVOT-006 Data Readout
Shares of CG Oncology rose 73% year-to-date as the company signals imminent results from its pivotal bladder-cancer trial for cretostimogene.
Rapport Therapeutics Showcases Pipeline Breadth at Cantor Conference
Bio-focused on its epilepsy drug RAP-219 after Phase II data showed a 77.8% seizure reduction and 24% freedom rate. Company holds $430 million in cash, funded through late 2029.
Del Monte Pacific Q1 Profit Triples to $16.1M Amid Persisting Debt Burden
Philippine foodmaker posts nearly threefold net profit rise in Q1 FY2027 as sales grow 9%, though negative equity of $579M at the holding level continues to weigh on the balance sheet.
Del Monte Pacific Q1 Profit Triples on International Growth
First-quarter net profit surged nearly three-fold to US$16.1 million as international sales drove revenue growth, though Philippine operations slipped and the company carried a heavy debt load with negative equity.
Del Monte Philippines Q1 profit triples on strong international demand
Net profit surged to $16.1 million in Q1 FY2027, up 193% year-over-year, as international markets drove growth despite commodity cost headwinds from the US-Iran conflict.
Intuit Reiterates Fiscal 2027 Revenue, Earnings Guidance
Intuit reaffirmed its full-year fiscal 2027 outlook at an investor day event, projecting revenue of $23.28 billion to $23.51 billion and non-GAAP diluted EPS of $22.88 to $23.12.
Jack Henry posts 7% revenue growth, outlines 2027 outlook at Goldman Sachs conference
The payments‑technology firm reported $2.54 billion in revenue for fiscal 2026, a 7% rise, and projected similar growth for fiscal 2027 while expanding margins and core wins.
Citius Pharmaceuticals Sees LYMPHIR Launch Gaining Traction at Moody Capital Conference
The biotech reported $7.1 million in LYMPHIR revenue through Q3 FY2024 with 77% gross margins, as it prepares for a full sales force deployment ahead of broader commercial rollout.
ORIC Pharmaceuticals details pipeline, financials at Wells Fargo healthcare conference
ORIC reports $388M cash, $1.31B market cap at Wells Fargo conference; Phase III prostate cancer readout expected H1 2028.
Lumexa Imaging Outlines Growth Strategy at Wells Fargo Healthcare Conference
The outpatient imaging operator described its expansion roadmap, margin outlook, and capital strategy as shares remain well below their 52-week high.
Chime lifts full-year revenue growth guidance to 30% and reports 20% Q2 volume rise
The fintech raised its revenue outlook, posted higher adjusted EBITDA margins and announced a 1.5‑times‑book acquisition of Stride Bank.
Sirius XM Targets $1.5B Free Cash Flow in 2026 as Ad Revenue Grows
CEO Jennifer Witz outlined free-cash-flow expansion, cost savings, and a YouTube partnership scaling into the second half at Goldman Sachs Communacopia.
Sagicor Targets 15% ROE by 2028 on Three Strategic Levers
CEO Andre Mousseau outlined plans to lift return on equity through Canadian balance-sheet optimization, U.S. annuity expansion, and Caribbean integration.
Sprinklr Posts Q2 EPS Beat, But Revenue Falls Short of Estimates
Customer experience platform provider Sprinklr reported non-GAAP EPS of $0.11, beating Wall Street’s $0.10 forecast, while revenue slipped to $213.7 million from the $215.56 million estimate.
Heartflow Stock Soars to All-Time High as Q2 Earnings Crush Estimates
Heartflow Inc. shares hit $51.26, buoyed by a 48% revenue jump and better-than-expected losses, prompting Stifel to raise its price target.
Sprinklr Posts 1% Revenue Growth, Raises Full-Year Subscription Outlook
Customer experience platform provider reported $213.7 million in Q2 revenue, with subscription revenue rising 3% and remaining performance obligations holding above $1 billion.
BillionToOne Reports 64% Revenue Growth With Margin Discipline at Wells Fargo Conference
The prenatal and oncology diagnostics company posted strong second-quarter results driven by oncology acceleration, while maintaining 30-plus percent operating margins in its prenatal business and expanding into health systems.
Amplitude Shares Drop After Conference Highlights Pricing Shifts and Growth Reacceleration
Revenue growth surged to 22% in the latest quarter, but shares fell in after-hours trading as management outlined an ongoing pricing restructuring expected to drive 5–10% transaction-level uplifts.
Box CFO Says AI and Enterprise Advanced Drive Fifth Straight Quarter of Revenue Acceleration
Box reported its fifth consecutive quarter of accelerating revenue growth at Citi's TMT conference, pointing to strong demand for its highest-tier offering and expanding AI adoption across customer accounts.
Community Health Systems revises 2026 guidance amid market pressures
Community Health Systems trims 2026 adjusted EBITDA guidance to $1.338 billion from $1.415 billion, citing commercial elective softness and exchange-related headwinds. The company reports second-quarter EBITDA $60 million to $65 million below expectations.
Microchip Forecasts 40% Revenue Growth for September Quarter, Margins Steady Near 67%
Microchip Technology guided the September quarter to 40% year-over-year revenue growth at the midpoint, with gross margins expected around 66.5%, as data-center PCIe Gen 6 design wins and aerospace expansion drive the recovery.
Skillsoft shares drop after Q2 miss and lowered revenue outlook
Skillsoft posted a wide revenue miss in its second fiscal quarter but reported EBITDA margin improvement to 34%, then cut its full-year revenue outlook as consumer-business pressure intensified.
Navan Raises Full-Year Guidance After 35% Revenue Growth, AI Expansion
Corporate travel platform Navan reported Q2 FY27 revenue of $233 million, up 35%, and lifted full-year guidance. Shares fell 17% in after-hours trading despite the raised outlook.
LifeStance Health hits 52-week high on strong second-quarter results
LifeStance Health Group shares climbed to a 52-week high of $12.97 after the mental-health provider reported Q2 earnings that more than doubled Wall Street expectations and raised its full-year outlook.